New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
06:54 EDTPFE, AZN, BLKBlackRock wants AstraZeneca to resume discussions with Pfizer, Reuters says
AstraZeneca's (AZN) biggest shareholder, BlackRock (BLK), wants the pharmaceutical maker to resume discussions with Pfizer (PFE) regarding a possible sale at some point, but it supports its choice to reject Pfizer's current offer, according to Reuters, citing two people familiar with the matter. Reference Link
News For BLK;AZN;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 20, 2015
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
06:02 EDTAZNClovis pullback on Astra data a buying opportunity, says Mizuho
Subscribe for More Information
April 17, 2015
06:52 EDTAZNAstraZeneca granted FDA orphan drug designation for selumetinib
AstraZeneca announced that the FDA has granted orphan drug designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye.
06:50 EDTAZNAstra reports median progression free survival of 13.5 months in AURA study
Subscribe for More Information
April 16, 2015
09:12 EDTAZNAstraZeneca granted orphan status for melanoma treatment
Subscribe for More Information
07:58 EDTAZNAstraZeneca's MedImmune, Immunocore announce new collaboration agreement
Subscribe for More Information
05:48 EDTBLKBlackRock reports Q1 AUM up 8%
Subscribe for More Information
05:47 EDTBLKBlackRock reports Q1 long-term net inflows of $70.4B
Flows were positive across all long-term asset classes, client types, regions and investment styles, with active net inflows of $32B and index net inflows of $38B. Reports Q1 Institutional long-term net inflows of $21B. Long-term net inflows were positive across all regions, with net inflows of $47.5B, $17.7B and $5.2B from clients in the Americas, EMEA and Asia-Pacific, respectively. At March 31, 2015, BlackRock managed 62% of its long-term AUM for investors in the Americas and 38% for clients in EMEA and Asia-Pacific.
05:45 EDTBLKBlackRock reports Q1 adjusted EPS $4.89, consensus $4.52
Subscribe for More Information
April 15, 2015
11:50 EDTAZNAstraZeneca initiated with a Buy at Societe Generale
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information
07:49 EDTBLKJPMorgan to hold a conference
Public Finance Transportation & Utility Conference is being held in New York on April 15-16.
07:41 EDTAZNEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
14:16 EDTBLKBlackRock April volatility elevated at 38 into Q4 and outlook
Subscribe for More Information
12:06 EDTAZNFDA panel accepts Onglyza's safety profile in 13-1 vote
Subscribe for More Information
07:15 EDTAZNFDA Endocrinologic & Metabolic Drugs Advisory Committee holds a meeting
Subscribe for More Information
April 13, 2015
15:12 EDTPFEMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.
08:58 EDTAZNMerck may have positive read through from briefing docs, says SunTrust
Subscribe for More Information
08:54 EDTAZNAstraZeneca has negative read through from briefing docs, says SunTrust
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use